2seventy bio (NASDAQ:TSVT) and MorphoSys (NASDAQ:MOR) Critical Comparison

MorphoSys (NASDAQ:MORGet Free Report) and 2seventy bio (NASDAQ:TSVTGet Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Valuation and Earnings

This table compares MorphoSys and 2seventy bio”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28 million 11.99 -$205.35 million ($3.48) -5.45
2seventy bio $48.37 million 5.50 -$217.57 million ($0.10) -50.00

MorphoSys has higher revenue and earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MorphoSys and 2seventy bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
2seventy bio -207.25% -53.65% -23.67%

Analyst Recommendations

This is a breakdown of current ratings for MorphoSys and 2seventy bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys 0 0 0 0 0.00
2seventy bio 0 3 0 0 2.00

2seventy bio has a consensus target price of $5.00, indicating a potential upside of 0.00%. Given 2seventy bio’s stronger consensus rating and higher probable upside, analysts clearly believe 2seventy bio is more favorable than MorphoSys.

Insider & Institutional Ownership

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 7.2% of 2seventy bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

2seventy bio beats MorphoSys on 8 of the 13 factors compared between the two stocks.

About MorphoSys

(Get Free Report)

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

About 2seventy bio

(Get Free Report)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.